Abstract
Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.
Current Pharmacogenomics and Personalized Medicine
Title:Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors
Volume: 16 Issue: 2
Author(s): Wei-Hua Shao, Lei-Yun Wang and Ji-Ye Yin*
Affiliation:
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008,China
Keywords: PARP inhibitor, DNA repair, pharmacogenetics, drug response, cancer, veliparib, talazoparib.
Abstract: Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
Export Options
About this article
Cite this article as:
Shao Wei-Hua , Wang Lei-Yun and Yin Ji-Ye *, Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors, Current Pharmacogenomics and Personalized Medicine 2018; 16 (2) . https://dx.doi.org/10.2174/1875692116666180821152601
DOI https://dx.doi.org/10.2174/1875692116666180821152601 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subject Index To Volume 9
Combinatorial Chemistry & High Throughput Screening Management of Ovarian Cancer in Elderly
Reviews on Recent Clinical Trials Identifying Molecular Biomarker for the Lung Squamous Cell Carcinoma by Integrating Multifactorial Data
Current Bioinformatics Apoptosis-related BCL2-family Members: Key Players in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Engineered Polymer-Based Nanomaterials for Diagnostic, Therapeutic and Theranostic Applications
Mini-Reviews in Medicinal Chemistry Anti-Carcinogenic Effects of Carnosol-An Updated Review
Current Drug Discovery Technologies Cyclotron Production of PET Radiometals in Liquid Targets: Aspects and Prospects
Current Radiopharmaceuticals Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews Comparing the Molecular Pharmacology of CGRP and Adrenomedullin
Current Protein & Peptide Science PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets p42.3 in Gastric Carcinoma: A Novel Biomarker and Promising Therapeutic Target
Letters in Drug Design & Discovery Modulation of Carbonic Anhydrase 9 (CA9) in Human Brain Cancer
Current Pharmaceutical Design Epigenetic Regulation of Osteogenic Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Formulation and Evaluation of in vitro Cytotoxicity of Carboplatin Niosomes
Drug Delivery Letters Natural Compounds Containing a Condensed Cyclopropane Ring. Natural and Synthetic Aspects
Current Organic Chemistry Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery
Current Topics in Medicinal Chemistry Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Expression, Purification, Crystallization and Preliminary X-Ray Analysis of Human Spindlin1, an Ovarian Cancer-Related Protein
Protein & Peptide Letters